Oxidative Stress in Tumor Genesis, Progression and Therapy—2nd Edition

Dear Colleagues,

Reactive oxygen and nitrogen species (ROS/RNS) are involved in multiple aspects of cancer, including oncogenesis, progression and therapy response. While an unbalanced ROS/RNS production and detoxification favor mutagenesis and tumor promotion, oxidative stress induced by xenobiotics, classical chemotherapies, and novel anticancer agents promotes cancer cell death. On the other hand, natural and synthetic antioxidants exert chemoprotective effects against several mutagens, while they may also stimulate growth and metastasis in some cancer models. Thus, it is becoming clear that a fine-tuned control of ROS/RNS production and detoxification is essential for both chemoprevention and cancer cells survival, and the disruption of redox pathways in normal and cancerous cells may dictate both oncogenesis and cancer cells death. Taking this into account, the pharmacological modulation of redox pathways, including thioredoxin/thioredoxin reductase-1, peroxiredoxins, and glutathione synthesis/recycling metabolism, as well as interference with the master regulator of antioxidant response, the nuclear factor erythroid 2-related factor 2 (NRF2), have been emerging as therapeutic opportunities to sensitize cancers to classical drugs and novel compounds.  Understanding cancer cells response to redox active compounds and their effects upon malignance phenotypes (proliferation, invasion/migration, angiogenesis, metastasis and chemoresistance) may open up new avenues in cancer prevention and treatment. We invite authors to submit original research or review articles for the 2nd Edition of this Special Issue in Antioxidants.

The topics include but are not limited to:

1. Novel anticancer or chemoprotective agents interfering with redox pathways;
2. Effect of redox active compounds upon proliferation; invasion and metastasis;

• ROS/RNS and chemoresistance;

1. Redox susceptibility of cancers;
2. Antioxidants in cancer therapy;
3. Antioxidants in prevention of anticancer drug side effects.

We look forward to your contributions.

Dr. Alfeu Zanotto-Filho
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Antioxidants is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• oxidative stress and cancer cells survival
• antioxidant pathways in cancer cells survival
• ROS/RNS in oncogenesis and tumor progression
• novel redox-active anticancer drugs
• redox susceptibility in cancer
• antioxidants and chemoprotection
• natural and synthetic antioxidants
• ROS/RNS-dependent apoptosis, necrosis and ferroptosis